Back to Browse Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 1

mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report

Authors Ibeas P, Cantos B, Provencio M.

Published 8 November 2011 Volume 2011:1 Pages 19—22


Review by Single-blind

Peer reviewer comments 3

Patricia Ibeas, Blanca Cantos, Mariano Provencio
Clinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, Spain

Abstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.

Keywords: everolimus, positron emission tomography, chemotherapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

IL-15 as a potential target in leukemia

Xiong Y, Bensoussan D, Decot V

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:55-63

Published Date: 9 April 2015

MicroRNAs as B-cell lymphoma biomarkers

Manterola L, Fernandez-Mercado M, Larrea E, Goicoechea I, Arestin M, Armesto M, Hernandez L, Lawrie CH

Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:25-34

Published Date: 4 February 2015

Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies

Gopalakrishnan S, Tan D

Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:19-24

Published Date: 18 April 2013

Eribulin mesylate in the treatment of metastatic breast cancer

Jain S, Cigler T

Biologics: Targets and Therapy 2012, 6:21-29

Published Date: 11 January 2012

The evaluation and optimal use of rituximab in lymphoid malignancies

Robak T, Robak P, Smolewski P

Blood and Lymphatic Cancer: Targets and Therapy 2012, 2:1-16

Published Date: 4 January 2012

Reasons for delaying or engaging in early sexual initiation among adolescents in Nigeria

Ankomah A, Mamman-Daura F, Omoregie G, Anyanti J

Adolescent Health, Medicine and Therapeutics 2011, 2:75-84

Published Date: 9 September 2011

Garlic compounds selectively kill childhood pre-B acute lymphoblastic leukemia cells in vitro without reducing T-cell function: Potential therapeutic use in the treatment of ALL

Greg Hodge, Stephen Davis, Michael Rice, Heather Tapp, Ben Saxon, Tamas Revesz

Biologics: Targets and Therapy 2008, 2:143-149

Published Date: 7 March 2008